While one of the proteins linked to EDII and incident cognitive impairment (CXCL10) has been nominated as a therapeutic target for AD, three candidate proteins (CCL2, CXCL10, and HGF) are therapeutic targets of ongoing clinical trials for non-neurologic disease (Supplementary Table 21). The gene discussed is CCL2; the disease is Cognitive impairment.